More Articles

Access and Evidence

Pragmatic Trials: The Real-World Data Revolution

Adam Chapman, (Sep 27, 2017)

Insights derived from real-world data are changing every facet of pharma but its impact on clinical trials may prove to be a crowning achievement

The Sales Survival Guide

Nancy Bergquist, (Sep 26, 2017)

To deliver more valuable customer interactions, sales reps and account managers need support and training

Digital: Let Customers Weave Their Own Webs

Hugh Gosling, (Sep 20, 2017)

To succeed in digital, reps must customize the message and hand control over to the customer
Patients and Medical

Redefining Medical Need

Lucy Fulford, (Sep 15, 2017)

To truly understand unmet medical need, we need to stop focusing on the disease and start talking to patients, says Allergan CMO, Gavin Corcoran

Changing The DNA

Danielle Barron, (Sep 15, 2017)

A patient-first strategy is important but without the culture to back it up, companies will struggle to truly embrace patient-centricity.
Patients and Medical

Asking The Big Questions

Adam Chapman, (Sep 13, 2017)

Pharma’s shift towards preventative care reflects its wider role within the healthcare system, says Anne Beal, Global Head of Patient Solutions, Sanofi.
Access and Evidence

Indication-Based Pricing: A Utopian Ideal?

Adam Chapman, (Sep 11, 2017)

The potential benefits of moving to a variable pricing model based on indication are manifold, but is the US healthcare system ready?

An Atypical Patient Advocate

Danielle Barron, (Sep 11, 2017)

Merck EVP Dr. Julie Gerberding has not followed a classic professional path, either for a physician or a pharma executive. Instead, her unique career has been guided by a simple compass – the needs of patients

Ipsen: Making Patient-Centricity A Reality

Lucy Fulford, (Sep 6, 2017)

The secret to embedding patient-centricity deep in an organization is to encourage colleagues to roll up their sleeves. After all, practice makes perfect, says Ipsen Chief Patient Affairs Officer
Patients and Medical

Pharma’s social contract: time for everyone to join in

Paul Simms, (Sep 6, 2017)

One year on, Brent Saunders of Allergan suggests to Paul Simms the case for expanding the pharma-patient social contract across the industry